amyotrophic lateral sclerosis is now commonly referred to as “ALS.” It is a neurological disease that affects motor neurons, the nerve cells in the brain and spinal cord that control breathing ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial of AMX0114, ...

MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

The FDA has granted approval for Zydus to proceed with the Phase II(b) trial of Usnoflast for amyotrophic lateral sclerosis (ALS) treatment.

Amyotrophic Lateral Sclerosis [ALS] is a type of disorder characterized as a progressive disorder where the nerve cells of the brain and spinal cord ... to evaluate a change in disease severity ...

Gehrig played with the New York Yankees for 17 years and was known as “The Iron Horse” due to his ability to play baseball, ...

CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...

While he was the first person to have electrodes implanted in his brain to restore function to his own body, others have had ...